These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Treatment of nephrotic syndrome with levamisole.
    Author: Tanphaichitr P, Tanphaichitr D, Sureeratanan J, Chatasingh S.
    Journal: J Pediatr; 1980 Mar; 96(3 Pt 1):490-3. PubMed ID: 6965715.
    Abstract:
    Considerable evidence suggests a role of abnormal T-cell lymphocyte functions in the pathogenesis of minimal lesion nephrotic syndrome. The mean +/- SD T-cell lymphocytes as determined by %E-rosettes among 10 children after 24 to 84 months of complete remission was 66.7 +/- 4.5; this is statistically different from that of seven children with minimal lesion nephrotic syndrome during relapse, 33.5 +/- 9.5 (P less than 0.01). After levamisole therapy at 1.5 to 3.9 mg/kg/dose twice weekly for one to six months, the mean +/- SD %E-rosettes in the latter group was 69.3 +/- 3.9, which is not statistically different from that in the group with complete remission after conventional treatment with steroids. Those treated with levamisole also had a complete remission without any side effects.
    [Abstract] [Full Text] [Related] [New Search]